The antagonistic anti-TIGIT antibody OMP-313M32 (NCT03119428) was evaluated as a single drug, and two antibodies were combined with PD-1 blockers to evaluate MTIG7192A (NCT02794571) and BMS-986207 in some advanced primary brain tumours or other primary tumours (NCT02913313). Here, TIGIT is linked to neoplasm.